Navigation Links
Study Shows Stents Are Superior to Balloons Alone for Patients With Deep Venous Thrombosis
Date:5/6/2011

BALTIMORE, May 6, 2011 /PRNewswire/ -- Stenting is safe and effective and superior to balloon angioplasty for treatment of venous stenosis in patients with deep vein thrombosis (DVT), according to results from EVISTA-DVT, presented today as a Late-Breaking Clinical Trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions in Baltimore.

EVISTA-DVT focused on patients with blocked veins who had received clot-buster drug therapy (thrombolysis). Researchers found stenting was more effective than balloons alone at restoring and maintaining blood flow through the thigh veins.

"We are encouraged by these study results," said Mohsen Sharifi, MD, FSCAI, director of Arizona Cardiovascular Consultants and adjunct professor at A.T. Still University in Mesa, Ariz. "For patients with DVT, stenting is a viable option, as demonstrated by the success rates for patients studied in this trial."

DVT affects approximately 350,000 to 600,000 Americans each year. Blood clots form in a vein in the lower leg and thigh. If left untreated, the clot can block blood flow through the vein. If the clot moves through the bloodstream, it can get stuck in the lungs leading to pulmonary embolism and possibly death. It is estimated at least 100,000 deaths may be directly or indirectly related to DVT and blood clots that travel to the lungs. Inserting a stent – a tiny mesh tube – opens up the blockage that may cause future clot formation.

The trial included 141 patients who had initial clot-dissolving drug therapy, but continued to have blockage of their vein. Patients were randomly assigned to further treatment with stenting (71 patients) or balloon venoplasty alone (70 patients) to open up the blocked vein. Every six months researchers checked blood flow through the leg veins using ultrasound.

During a follow-up that averaged 35 months, three patients (4%) in the stent group and seven patients (10%) in the
'/>"/>

SOURCE Society for Cardiovascular Angiography and Interventions (SCAI)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
2. Reportlinker Adds Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development
3. Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study
4. New Biomarkers Study Could Lead to Better Malaria Vaccine Design
5. Columbia engineering study links ozone hole to climate change all the way to the equator
6. ACT Files European Clinical Trial Application for Phase 1/2 Study Using Embryonic Stem Cells to Treat Macular Degeneration
7. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
8. Scientists recreate brain cells from skin cells to study schizophrenia safely
9. Study finds public relatively unconcerned about nanotechnology risks
10. Newly Published Study Shows Dramatic Reduction in Hospital Acquired Infections
11. Catalysis Foundation for Health Selects BioFortis Labmatrix Database Software for International Tuberculosis Diagnostic Biomarker Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , a precision medicine software company that has developed a ... genomic, imaging and other biomedical data in research and clinical ... CEO of Aspera, an IBM Company, to its board as ... "We are pleased to welcome Michelle to ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... Wash. , Dec. 24, 2014   BioLife Solutions , ... and marketer of proprietary clinical grade hypothermic storage ... shipping products for cells and tissues  ("BioLife" or the ... Meeting of Stockholders on May 4, 2015 (the "Annual Meeting"). ...
(Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... TORONTO, Sept. 15, 2011 Generex Biotechnology Corporation ... update on the status of the previously announced ... ( www.antigenexpress.com ). The Company is ... review of several transaction opportunities, including both shell ...
... and SYDNEY, Sept. 14, 2011 HeartWare International, Inc. ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that CEO Doug Godshall is scheduled to ... 10:30 a.m. ET on Wednesday, September 21, 2011.  The ...
... 2011 Tengion, Inc. (NASDAQ: TNGN ), a ... President Finance and Chief Financial Officer of Tengion, will present ... September 19, 2011, at 1:30 pm EDT. ... "Calendar of Events" in the Investors section of the Company,s ...
Cached Biology Technology:Generex Provides Update on Spinout of Antigen Express 2Generex Provides Update on Spinout of Antigen Express 3Generex Provides Update on Spinout of Antigen Express 4HeartWare to Present at the UBS Global Life Sciences Conference 2Tengion to Present at UBS Global Life Sciences Conference 2
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
(Date:1/22/2015)... Issued by Small Cap IR. In 2011, Nilson Report,s annual ... merchants on the leading payment cards rose to $135.3 billion ... prepaid cards reached 6.54 billion.  Eight million credit card users ... 2012, and credit and debit card fraud resulted in $11.27 ...
(Date:1/22/2015)... NEW YORK , Jan. 22, 2015   EyeLock, Inc. ... announced it has appointed Steve Gerber to the ... Gerber will be responsible for leading development of mobile platforms ... 25 years of success and innovation in the semiconductor industry ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... January 11, 2010 The subtle but ongoing pressures of ... as autism, autoimmune diseases, and reproductive cancers, researchers write in ... Certain adaptations that once benefited humans may now be ... because of advancements in modern culture and medicine. ...
... , REDWOOD CITY, Calif. and ... in fingerprint identity and authentication solutions, has extended its ... Retail Anywhere , a leading developer of point-of-sale (POS) ... in North America, has integrated U.are.U® fingerprint ...
... significantly enhance household incomes and nutritional intake of ... new Stanford University study published in the Proceedings ... two-year study found that solar-powered pumps installed in ... Benin were a cost-effective way of delivering much-needed ...
Cached Biology News:Ongoing human evolution could explain recent rise in certain disorders 2Retail Anywhere Adds U.are.U Biometrics From DigitalPersona to Flagship Point of Sale Solution 2Retail Anywhere Adds U.are.U Biometrics From DigitalPersona to Flagship Point of Sale Solution 3Solar-powered irrigation significantly improves diet and income in rural sub-Saharan Africa 2Solar-powered irrigation significantly improves diet and income in rural sub-Saharan Africa 3Solar-powered irrigation significantly improves diet and income in rural sub-Saharan Africa 4
LabFax: Immunochemistry...
Mycoplasma Removal Agent (MRA) has been developed for cell culture, to combat the widespread problems caused by contamination of cell cultures with mycoplasma....
Request Info...
albumin from bovine serum (BSA), BODIPY® FL conjugate...
Biology Products: